Difference between revisions of "Team:NCTU Formosa"

Line 199: Line 199:
 
      <div class="photocontent2"><h2>What's new</h2>
 
      <div class="photocontent2"><h2>What's new</h2>
 
  APOllO E.Cotector:<br>   
 
  APOllO E.Cotector:<br>   
−
Our organization create a customized scFv detection platform by co-transforming any desired combination of plasmids. ScFv utilizing antigen-antibody-interaction can act as probes. Our E.Cotector can therefore have the function of a detector.
+
Our organization create a customized scFv detection platform by co-transforming any desired plasmid. ScFv utilizing antigen-antibody interaction can act as probes. Our E.Cotector can therefore have the function of a detector.
 
      </div> </div>
 
      </div> </div>
 
              
 
              
Line 205: Line 205:
 
    <div class="photo3-3"></div>
 
    <div class="photo3-3"></div>
 
             
 
             
−
        <div class="photocontent3"><h2>What we care</h2>
+
        <div class="photocontent3"><h2>What do we care</h2>
 
         
 
         
 
In 2015, we focus on helping doctors select the appropriate candidates for monoclonal-antibody targeted drug for patient's treatment in a more inexpensive way. If the cost for diagnosis decreases, more people can afford it. Therefore, more people can be prescribed and treated, lowering the mortality rate of cancer.<br>
 
In 2015, we focus on helping doctors select the appropriate candidates for monoclonal-antibody targeted drug for patient's treatment in a more inexpensive way. If the cost for diagnosis decreases, more people can afford it. Therefore, more people can be prescribed and treated, lowering the mortality rate of cancer.<br>

Revision as of 14:51, 15 September 2015

1
The only thing we detect is everything.

Who are we

NCTU_Formosa created an organization-APOllO, which stands for Almighty Probe of scFv Organization. APOllO devoted to developing detection technology by utilizing antibodies. In 2015, We cooperated with iGEM with Synthetic Biology to develop a brand new detection platform.

What's new

APOllO E.Cotector:
Our organization create a customized scFv detection platform by co-transforming any desired plasmid. ScFv utilizing antigen-antibody interaction can act as probes. Our E.Cotector can therefore have the function of a detector.

What do we care

In 2015, we focus on helping doctors select the appropriate candidates for monoclonal-antibody targeted drug for patient's treatment in a more inexpensive way. If the cost for diagnosis decreases, more people can afford it. Therefore, more people can be prescribed and treated, lowering the mortality rate of cancer.